SEMINOMA
Clinical trials for SEMINOMA explained in plain language.
Never miss a new study
Get alerted when new SEMINOMA trials appear
Sign up with your email to follow new studies for SEMINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Testicular cancer study seeks better chemo combo to prevent return
Disease control OngoingThis study compares two chemotherapy treatments for men with stage I seminoma testicular cancer that has a higher risk of coming back. One group gets a single course of carboplatin, the current standard. The other gets a stronger combination of three drugs (BEP). The goal is to s…
Matched conditions: SEMINOMA
Phase: PHASE3 • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated May 17, 2026 02:41 UTC
-
Could less treatment be just as good for some testicular cancers?
Disease control OngoingThis study is for people with stage IIA or IIB seminoma, a type of testicular cancer. It tests a reduced-intensity combination of chemotherapy and radiation to see if it can control the cancer as well as standard treatment while causing fewer side effects. About 135 participants …
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 17, 2026 02:40 UTC
-
New hope for incurable cancer? cabozantinib trial targets resistant germ cell tumors
Disease control OngoingThis study tests the drug cabozantinib in 50 adults with germ cell tumors (like testicular or ovarian cancer) that have not responded to standard chemotherapy. The goal is to see if the drug can shrink tumors or stop them from growing for at least 3 months. Participants take the …
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: Jennifer King • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Immunotherapy duo takes on resistant germ cell cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, can shrink tumors in people with germ cell cancers that have come back or not responded to standard treatment. About 30 adults with measurable disease are participating. The main goal is to s…
Matched conditions: SEMINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:04 UTC
-
Blood marker may predict cancer return in testicular cancer patients
Knowledge-focused OngoingThis study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers are collecting blood samples from 956 newly diagnosed patients and tracking their health over time. The goal is to see if this…
Matched conditions: SEMINOMA
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC